These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29859754)

  • 41. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
    Patel DA; Xi J; Luo J; Hassan B; Thomas S; Ma CX; Campian JL
    Breast Cancer Res Treat; 2019 Apr; 174(2):443-452. PubMed ID: 30604000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC.
    Zhao Q; Chen G; Ye L; Shi S; Du S; Zeng Z; He J
    Radiat Oncol; 2019 May; 14(1):86. PubMed ID: 31133034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
    Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
    J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
    Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
    BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
    Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
    Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer.
    Punjabi A; Barrett E; Cheng A; Mulla A; Walls G; Johnston D; McAleese J; Moore K; Hicks J; Blyth K; Denholm M; Magee L; Gilligan D; Silverman S; Qureshi M; Clinch H; Hatton M; Philipps L; Brown S; O'Brien M; McDonald F; Faivre-Finn C; Hiley C; Evison M
    Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):e331-e338. PubMed ID: 33863615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival Impact of Cardiac Dose Following Lung Stereotactic Body Radiotherapy.
    Wong OY; Yau V; Kang J; Glick D; Lindsay P; Le LW; Sun A; Bezjak A; Cho BCJ; Hope A; Giuliani M
    Clin Lung Cancer; 2018 Mar; 19(2):e241-e246. PubMed ID: 28941961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
    Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Definitive radiotherapy alone over 60 Gy for patients unfit for combined treatment to stage II-III non-small cell lung cancer: retrospective analysis.
    Joo JH; Song SY; Kim SS; Jeong Y; Jeong SY; Choi W; Choi EK
    Radiat Oncol; 2015 Dec; 10():250. PubMed ID: 26635014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Definitive chemotherapy and radiotherapy in patients with stage II non-small cell lung cancer: A population-based outcomes study.
    Sampath S; Hall M; Schultheiss TE
    Lung Cancer; 2015 Oct; 90(1):61-4. PubMed ID: 26231092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.
    Xu Y; Zheng X; Bai X; Li P; Ma H; Wang J; Hu X; Chen M
    Oncotarget; 2017 Jul; 8(30):49084-49092. PubMed ID: 28467775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery.
    Wu AJ; Garay E; Foster A; Hsu M; Zhang Z; Chaft JE; Huang J; Rosenzweig KE; Rimner A
    Clin Lung Cancer; 2017 May; 18(3):e161-e168. PubMed ID: 28302437
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer.
    Tang C; Liao Z; Hess K; Chance WW; Zhuang Y; Jensen G; Xu T; Komaki R; Gomez DR
    Acta Oncol; 2016 Aug; 55(8):1022-8. PubMed ID: 27055359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of induction chemotherapy on the dosimetric parameters of subsequent radiotherapy: an investigation of 30 consecutive patients with locally-advanced non-small cell lung cancer and modern radiation planning techniques.
    Grant JD; Sobremonte A; Hillebrandt E; Allen PK; Gomez DR
    Radiat Oncol; 2015 Jan; 10():32. PubMed ID: 25636372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship between dosimetric factors, side effects, and survival in patients with non-small cell lung cancer treated with definitive radiotherapy.
    Okumus D; Sarihan S; Gozcu S; Sigirli D
    Med Dosim; 2017 Autumn; 42(3):169-176. PubMed ID: 28506589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
    Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.
    Jeremic B; Shibamoto Y; Acimovic L; Djuric L
    J Clin Oncol; 1995 Feb; 13(2):452-8. PubMed ID: 7844608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.